Xiaoming Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiaoming Feng has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chunren Wang
National Institute for Food and Drug Control
2 shared publications - Qianqian Han
National Institutes for Food and Drug Control, Beijing 100050, China
2 shared publications - Zhaopeng Yang
Division of Biomaterials and Tissue Engineering, National Institutes for Food and Drug Control , Beijing, P.R. China
2 shared publications - Anqi Wang
Division of Biomaterials and Tissue Engineering, National Institutes for Food and Drug Control , Beijing, P.R. China
1 shared publication Jianwu Dai
Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100080, China
1 shared publication- Linnan Ke
Institute for Medical Devices Control, National Institutes for Food and Drug Control, No. 31 Huatuo Road, Beijing 102629, China
1 shared publication
Latest Publications
- 1 December 2015
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 21 (23-24) , 2806-2811
Premarket Regulation of Tissue Engineered Medical Products in China
Tissue engineered medical products (TEMPs) employ state-of-the-art technologies and offer the patients with alternative clinical options for diseases that conventional treatments may fail or be incompetent. However promising, this technology is comparatively new with very limited hands-on experiences with both manufacturing and clinical therapy. Of great significance to products with such complexity and novelty is the establishment of a complete jurisdiction framework and a standardization database so that the safety of the technique in clinical treatment can be ensured. Although different regulatory routes are adopted in different countries, risks are generally considered to be derived from the cellular components within the product, the material scaffolds and potentially from the final products. This article is to provide an insight of the regulatory considerations and the role of China Food and Drug Administration (CFDA) in the supervision of TEMPs.
- 1 December 2015
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 21 (23-24) , 2806-2811
Premarket Regulation of Tissue Engineered Medical Products in China
Tissue engineered medical products (TEMPs) employ state-of-the-art technologies and offer the patients with alternative clinical options for diseases that conventional treatments may fail or be incompetent. However promising, this technology is comparatively new with very limited hands-on experiences with both manufacturing and clinical therapy. Of great significance to products with such complexity and novelty is the establishment of a complete jurisdiction framework and a standardization database so that the safety of the technique in clinical treatment can be ensured. Although different regulatory routes are adopted in different countries, risks are generally considered to be derived from the cellular components within the product, the material scaffolds and potentially from the final products. This article is to provide an insight of the regulatory considerations and the role of China Food and Drug Administration (CFDA) in the supervision of TEMPs.
- 1 October 2013
- Vol. 30 (5) , 1058-62
[The preparation and bioactivity assessment of gene recombinant fibrin-binding brain derived neurotrophic factor].
Using the E. coli, we fabricated the gene reconstructed brain derived neurotrophic factor with a fibrin binding domain (FBD-BDNF). We then tested the neurotrophic bioactivity and fibrin-binding ability of the FBD-BDNF. The E. coli was used to express the recombinant protein. The inclusion body was purified with column chromatography and renaturated to construct the right 3D formation. In this study, we successfully fabricated the FBD-BDNF and tested the binding ability and neurotrophic activity. The results demonstrated that FBD-BDNF had special binding ability of fibrin and significant neurotrophic activity for DRG cells. FBD-BDNF could have a promising application prospect in nerve tissue engineering.
- 1 October 2013
- Vol. 30 (5) , 1058-62
[The preparation and bioactivity assessment of gene recombinant fibrin-binding brain derived neurotrophic factor].
Using the E. coli, we fabricated the gene reconstructed brain derived neurotrophic factor with a fibrin binding domain (FBD-BDNF). We then tested the neurotrophic bioactivity and fibrin-binding ability of the FBD-BDNF. The E. coli was used to express the recombinant protein. The inclusion body was purified with column chromatography and renaturated to construct the right 3D formation. In this study, we successfully fabricated the FBD-BDNF and tested the binding ability and neurotrophic activity. The results demonstrated that FBD-BDNF had special binding ability of fibrin and significant neurotrophic activity for DRG cells. FBD-BDNF could have a promising application prospect in nerve tissue engineering.